Acute-on-chronic liver failure: an update

Ruben Hernaez, Elsa Solà, Richard Moreau, Pere Ginès, Ruben Hernaez, Elsa Solà, Richard Moreau, Pere Ginès

Abstract

Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission. Most of the patients will have a clear prognosis between day 3 and 7 of hospital admission and clinical decisions such as evaluation for liver transplant or discussion over goals of care could be tailored using clinical scores. Bioartificial liver support systems, granulocyte-colony stimulating factors or stem-cell transplant are in the horizon of medical care of this patient population; however, data are too premature to implement them as standard of care.

Keywords: LIVER CIRRHOSIS; LIVER FAILURE.

Conflict of interest statement

Competing interests: PG declares that he has received research funding from Ferring Pharmaceuticals, Grifols S.A. and Sequana Medical. He has participated on Advisory Boards for Ferring Pharmaceuticals, Promethera and Novartis.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Inflammation caused by microbes. Top: Microbes (bacteria, viruses, fungi) induce inflammation via two classes of molecules: pathogen-associated molecular patterns (PAMPs) and virulence factors. Sensors of the innate immune system recognise the invading microbe via recognition of PAMPs, which are conserved molecular patterns (structural feature recognition). Sensors are known as pattern-recognition receptors. The second class of microbial inducers of inflammation includes a large number of virulence factors. Most of these factors are generally not recognised by dedicated receptors but can be sensed via the effects of their activity (functional feature recognition). For example, there are bacterial virulence factors which cause modifications and inactivation of host Rho GTPases and these alterations are sensed by the Pyrin inflammasome. Infection may be associated with tissue damage caused by the bacteria or by the immune response to bacteria. Tissue damage can induce inflammation which is committed to tissue repair (see text and reference32). Bottom: Proposed interventions. MELD, Model For End-Stage Liver Disease score.
Figure 2
Figure 2
Relationship between organ failure and mortality in acute-on-chronic liver failure (ACLF). Twenty-eight-day mortality rates of patients with decompensated cirrhosis with (red bars) and without (green bars) ACLF according to the diagnostic criteria proposed in the CANONIC study. Patients are divided into the following categories: patients with no organ failure (OF); patients with a single non-kidney organ failure without kidney dysfunction (KD; a serum creatinine level of 1.5–1.9 mg/dL) or brain dysfunction (BD; grade 1–2 hepatic encephalopathy); patients with a single kidney failure; patients with a single non-kidney organ failure with KD and/or BD; patients with two organ failures and patients with three or more organ failures. Adapted with permission from Arroyo et al.
Figure 3
Figure 3
Comparison of the area under the receiver operating curves (AUROCs) to predict 28-day (panel A) and 90-day (panel B) mortality of the chronic liver failure Consortium (CLIF-C) acute-on-chronic liver failure (ACLF) score compared with Model For End-Stage Liver Disease (MELD), Model For End-Stage Liver Disease sodium score (MELD-Na) and Child-Pugh-Turcotte scores (CPs). Adapted with permission from Jalan et al.
Figure 4
Figure 4
Proposed algorithm for the management of patients with acute-on-chronic liver failure (ACLF) or decompensated cirrhosis. A proposed management strategy for patients with ACLF based on mortality rate data from the CANONIC study. The first step is the assessment of ACLF grade at days 3–7 after initiation of medical management, including organ support. Liver transplantation should be assessed in all patients with ACLF because of high 90-day mortality rates (>20%). Liver transplantation should be performed as early as possible in patients with ACLF grade 2 and grade 3 as they are at considerable risk of short-term (28-day) mortality. In the case of contraindication of liver transplantation, the presence of four or more organ failures (OFs) or a Chronic Liver Failure Consortium (CLIF-C) ACLF score of >64 at days 3–7 after diagnosis could indicate the futility of care. ICU, intensive care unit. Adapted from Gustot et al and obtained from Arroyo et al with permission.

References

    1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838–51. 10.1016/S0140-6736(08)60383-9
    1. Ginés P, Quintero E, Arroyo V, et al. . Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122–8. 10.1002/hep.1840070124
    1. Kjaergard LL, Liu J, ls-Nielsen B, et al. . Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217–22. 10.1001/jama.289.2.217
    1. Sarin SK, Kumar A, Almeida JA, et al. . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269–82. 10.1007/s12072-008-9106-x
    1. Sarin SK, Kedarisetty CK, Abbas Z, et al. . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014;8:453–71. 10.1007/s12072-014-9580-2
    1. Wlodzimirow KA, Eslami S, Abu-Hanna A, et al. . A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int 2013;33:40–52. 10.1111/j.1478-3231.2012.02790.x
    1. Bajaj JS, O'Leary JG, Reddy KR, et al. . Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014;60:250–6. 10.1002/hep.27077
    1. Jalan R, Yurdaydin C, Bajaj JS, et al. . Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014;147:4–10. 10.1053/j.gastro.2014.05.005
    1. Moreau R, Jalan R, Gines P, et al. . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–37, 1437.e1–9 10.1053/j.gastro.2013.02.042
    1. Jalan R, Saliba F, Pavesi M, et al. . Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61:1038–47. 10.1016/j.jhep.2014.06.012
    1. Garg V, Garg H, Khan A, et al. . Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142:505–12. 10.1053/j.gastro.2011.11.027
    1. Escorsell Mañosa À, Mas Ordeig A. [Acute on chronic liver failure]. Gastroenterol Hepatol 2010;33:126–34. 10.1016/j.gastrohep.2009.10.003
    1. Sargenti K, Prytz H, Nilsson E, et al. . Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure. Scand J Gastroenterol 2015;50:875–83. 10.3109/00365521.2015.1017834
    1. Shi Y, Yang Y, Hu Y, et al. . Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015;62:232–42. 10.1002/hep.27795
    1. Li H, Chen LY, Zhang NN, et al. . Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep 2016;6:25487 10.1038/srep25487
    1. Abbas Z, Shazi L. Pattern and profile of chronic liver disease in acute on chronic liver failure. Hepatol Int 2015;9:366–72. 10.1007/s12072-015-9627-z
    1. Wong RJ, Aguilar M, Cheung R, et al. . Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–55. 10.1053/j.gastro.2014.11.039
    1. Du WB, Li LJ, Huang JR, et al. . Effects of artificial liver support system on patients with acute or chronic liver failure. Transplant Proc 2005;37:4359–64. 10.1016/j.transproceed.2005.11.044
    1. Xia Q, Dai X, Zhang Y, et al. . A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients. PLoS ONE 2013;8:e64379 10.1371/journal.pone.0064379
    1. Kedarisetty CK, Sarin SK, Anand L, et al. . Liver failure determines the extra-hepatic organ failure and outcome in patients with acute-on-chronic liver failure: analysis of 1363 patients of AARC Data Base. Hepatology 2014;60:556A.
    1. Shi Y, Zheng MH, Yang Y, et al. . Increased delayed mortality in patients with acute-on-chronic liver failure who have prior decompensation. J Gastroenterol Hepatol 2015;30:712–8. 10.1111/jgh.12787
    1. Wehler M, Kokoska J, Reulbach U, et al. . Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001;34:255–61. 10.1053/jhep.2001.26522
    1. Cholongitas E, Senzolo M, Patch D, et al. . Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006;23:883–93. 10.1111/j.1365-2036.2006.02842.x
    1. Bernsmeier C, Pop OT, Singanayagam A, et al. . Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 2015;148:603–615.e14. 10.1053/j.gastro.2014.11.045
    1. Claria J, Stauber R, Coenraad MJ, et al. . Systemic Inflammation in decompensated cirrhosis. Characterization and role in acute on chronic liver failure. Hepatology 2016;64:1249–64. 10.1002/hep.28740
    1. Sole C, Sola E, Morales-Ruiz M, et al. . Systemic inflammatory response profile in acute-on-chronic liver failure and its relationship with prognosis. Sci Rep 2016;6:32341 10.1038/srep32341
    1. Arroyo V, Moreau R, Kamath PS, et al. . Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016;2:16041 10.1038/nrdp.2016.41
    1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428–35. 10.1038/nature07201
    1. Moreau R. The pathogenesis of ACLF: the inflammatory response and immune function. Semin Liver Dis 2016;36:133–40. 10.1055/s-0036-1583199
    1. Gustot T, Durand F, Lebrec D, et al. . Severe sepsis in cirrhosis. Hepatology 2009;50:2022–33. 10.1002/hep.23264
    1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805–20. 10.1016/j.cell.2010.01.022
    1. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015;16:343–53. 10.1038/ni.3123
    1. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008;8:279–89. 10.1038/nri2215
    1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54. 10.1056/NEJM199902113400607
    1. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010;140:771–6. 10.1016/j.cell.2010.03.006
    1. Rickard JA, O'Donnell JA, Evans JM, et al. . RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014;157:1175–88. 10.1016/j.cell.2014.04.019
    1. Christaki E, Giamarellos-Bourboulis EJ. The beginning of personalized medicine in sepsis: small steps to a bright future. Clin Genet 2014;86:56–61. 10.1111/cge.12368
    1. Cohen J, Vincent JL, Adhikari NK, et al. . Sepsis: a roadmap for future research. Lancet Infect Dis 2015;15:581–614. 10.1016/S1473-3099(15)70112-X
    1. Byl B, Roucloux I, Crusiaux A, et al. . Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993;104:1492–7. 10.1016/0016-5085(93)90361-F
    1. Navasa M, Follo A, Filella X, et al. . Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227–32. 10.1002/hep.510270507
    1. Michelena J, Altamirano J, Abraldes JG, et al. . Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015;62:762–72. 10.1002/hep.27779
    1. Louvet A, Wartel F, Castel H, et al. . Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137:541–8. 10.1053/j.gastro.2009.04.062
    1. Dominguez M, Miquel R, Colmenero J, et al. . Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009;136:1639–50. 10.1053/j.gastro.2009.01.056
    1. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012;335:936–41. 10.1126/science.1214935
    1. Jamieson AM, Pasman L, Yu S, et al. . Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 2013;340:1230–4. 10.1126/science.1233632
    1. Figueiredo N, Chora A, Raquel H, et al. . Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013;39: 874–84. 10.1016/j.immuni.2013.08.039
    1. Zagórska A, Través PG, Lew ED, et al. . Diversification of TAM receptor tyrosine kinase function. Nat Immunol 2014;15:920–8. 10.1038/ni.2986
    1. O'Brien AJ, Fullerton JN, Massey KA, et al. . Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014;20:518–23. 10.1038/nm.3516
    1. Gandoura S, Weiss E, Rautou PE, et al. . Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. J Hepatol 2013;58:936–48. 10.1016/j.jhep.2012.12.025
    1. Vincent JL, Moreno R, Takala J, et al. . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707–10.
    1. Gustot T, Fernandez J, Garcia E, et al. . Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243–52. 10.1002/hep.27849
    1. Gines P, Fernandez J, Durand F, et al. . Management of critically-ill cirrhotic patients. J Hepatol 2012;56(Suppl 1):S13–24. 10.1016/S0168-8278(12)60003-8
    1. Nadim MK, Durand F, Kellum JA, et al. . Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016;64:717–35. 10.1016/j.jhep.2015.10.019
    1. Finkenstedt A, Nachbaur K, Zoller H, et al. . Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl 2013;19:879–86. 10.1002/lt.23678
    1. Kribben A, Gerken G, Haag S, et al. . Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782–9. 10.1053/j.gastro.2011.12.056
    1. Heemann U, Treichel U, Loock J, et al. . Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36(Pt 1):949–58. 10.1053/jhep.2002.36130
    1. Hassanein TI, Tofteng F, Brown RS Jr, et al. . Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46:1853–62. 10.1002/hep.21930
    1. Bañares R, Nevens F, Larsen FS, et al. . Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153–62. 10.1002/hep.26185
    1. Duan XZ, Liu FF, Tong JJ, et al. . Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013;19:1104–10. 10.3748/wjg.v19.i7.1104
    1. Shi M, Zhang Z, Xu R, et al. . Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012;1:725–31. 10.5966/sctm.2012-0034

Source: PubMed

3
Prenumerera